Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | PNP | P00491 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.63 |
| ▸ | DPP4 | P27487 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | GAPDH | P04406 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxyadenosine SCHEMBL532825 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL12222478 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL593935 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL12222447 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL5982298 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL23982174 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL5982291 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL19506291 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL21637036 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 | |
| Deoxyadenosine SCHEMBL19877 | 1.00 | HIF1A (0.71) | HIF1ASMN1; SMN2PNPLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| WO-2025132708-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF HUNTINGTON'S DISEASE | PROQR THERAPEUTICS II B.V. (NL) | 2025-06-26 | — | — | WO | claimed |
| US-12319916-B2 | Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs | CAMP4 THERAPEUTICS CORPORATION (US) | 2025-06-03 | — | — | US | claimed |
| WO-2025104239-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CLASSIC GALACTOSEMIA | PROQR THERAPEUTICS II B.V. (NL) | 2025-05-22 | — | — | WO | claimed |
| EP-4555086-A1 | OLIGONUCLEOTIDES FOR ADAR-MEDIATED RNA EDITING AND USE THEREOF | ProQR Therapeutics II B.V. (NL) | 2025-05-21 | — | — | EP | claimed |
| US-20240336924-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CAMP4 THERAPEUTICS CORPORATION | 2024-10-10 | — | — | US | claimed |
| US-20240191231-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2024-06-13 | — | — | US | claimed |
| WO-2024013361-A1 | OLIGONUCLEOTIDES FOR ADAR-MEDIATED RNA EDITING AND USE THEREOF | PROQR THERAPEUTICS II B.V. (NL) | 2024-01-18 | — | — | WO | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| EP-3286338-B1 | AMPLIFICATION WITH PRIMERS OF LIMITED NUCLEOTIDE COMPOSITION | Atila Biosystems Incorporated (US) | 2023-11-01 | — | — | EP | claimed |
| US-5639603-A | PLURALITY OF DIFFERENT MEMBERS, EACH MEMBER COMPRISING SOLID SUPPORT, MULTIPLE COPIES OF COMPOUND BOUND TO EACH OF THE SUPPORTS; TAGGING, CLEAVING COMPOUNDS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1997-06-17 | — | — | US | claimed |
| EP-0726906-A1 | SYNTHESIZING AND SCREENING MOLECULAR DIVERSITY | AFFYMAX TECHNOLOGIES N.V. (AN) | 1996-08-21 | — | — | EP | claimed |
| WO-1995012608-A1 | SYNTHESIZING AND SCREENING MOLECULAR DIVERSITY | AFFYMAX TECHNOLOGIES N.V. (AN) | 1995-05-11 | — | — | WO | claimed |
| EP-0420862-B1 | PHARMACEUTICAL COMPOSITION CONTAINING DEOXYRIBONUCLEOSIDES FOR WOUND HEALING | PRO NEURON INC (US) | 1993-11-24 | — | — | EP | claimed |
| EP-0203959-B1 | NUCLEOTIDE ANALOGS FOR NUCLEIC ACID LABELING AND DETECTION | LIFE TECHNOLOGIES, INC. (US) | 1992-09-09 | — | — | EP | claimed |
| WO-1991019730-A1 | RNA HYDROLYSIS/CLEAVAGE | MONSANTO COMPANY (US) | 1991-12-26 | — | — | WO | claimed |
| EP-0173059-B1 | METHOD FOR THE PRODUCTION OF 2'-DEOXYADENOSINE COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 1989-11-29 | — | — | EP | claimed |
| EP-0203959-A4 | NUCLEOTIDE ANALOGS FOR NUCLEIC ACID LABELING AND DETECTION. | LIFE TECHNOLOGIES INC (US) | 1989-08-09 | — | — | EP | claimed |
| EP-0203959-A1 | NUCLEOTIDE ANALOGS FOR NUCLEIC ACID LABELING AND DETECTION. | LIFE TECHNOLOGIES INC (US) | 1986-12-10 | — | — | EP | claimed |
| WO-1986002929-A1 | NUCLEOTIDE ANALOGS FOR NUCLEIC ACID LABELING AND DETECTION | LIFE TECHNOLOGIES, INC. (US) | 1986-05-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336924-A1 | MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS | CPS1, CTPS1, CTPS2 | HIF1A 2083/4885SMN1; SMN2 1618/4885PNP 829/4885 |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | HIF1A 886/4885SMN1; SMN2 58/4885PNP 688/4885 |
| US-12319916-B2 | Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs | CPS1, CTPS1, CTPS2 | HIF1A 2083/4885SMN1; SMN2 1618/4885PNP 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.